Clopidogrel

BreastfeedingPediatric
  • TRADE NAME: Plavix (Bristol-Myers Squibb, Sanofi-Aventis)
  • INDICATIONS: Acute coronary syndrome, recent myocardial infarction, recent stroke, or established peripheral arterial disease
  • CLASS: Antiplatelet, Antiplatelet, thienopyridine
  • HALF-LIFE: 6 hours

Contra-indicated in patients with active pathological bleeding.

DIMINISHED EFFECTIVENESS IN POOR METABOLIZERS

See full prescribing information for complete boxed warning.

Our database has 71 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
GASTROINTESTINAL/HEPATIC
HEMATOLOGIC
NEUROMUSCULAR/SKELETAL
OCULAR
OTIC
RESPIRATORY
OTHER


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of clopidogrel in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top